$QDEL

QuidelOrtho Corp

QuidelOrtho develops and sells diagnostic testing solutions for healthcare providers and laboratories, as well as tests for individual, non-professional use. Its customers include physician offices, hospitals, clinical and reference laboratories, urgent care clinics, pharmacies, blood banks and donor centers. QuidelOrtho serves customers across more than 140 countries and territories and is headquartered in San Diego, California. Its business units are Labs, Molecular Diagnostics, Point of Care and Transfusion Medicine, which includes Immunohematology and Donor Screening. Products include laboratory instruments and tests, molecular testing platforms, rapid point-of-care tests, and instruments and tests for blood typing and infectious disease screening. QuidelOrtho also provides services such as technical support, training and laboratory consulting. It sells directly and through distributors. In some cases, it places instruments under long-term contracts and earns recurring sales from the assays, reagents and consumables customers are required to buy from it.

No enriched coverage for $QDEL in the last 7 days.

No SEC Form 4 filings for $QDEL in the last 30 days.

See all $QDEL insider activity →
High

QuidelOrtho Reports Third Quarter 2026 Financial Results

QuidelOrtho (QDEL) reported Q3 2026 revenue of $619M, down 12% YoY. Excluding respiratory, China, and U.S. Donor Screening, revenue grew 2-3%. Labs revenue declined 6% due to China pricing changes, but grew 3-4% outside China. Point of Care revenue dropped 27% due to a softer respiratory season. The company launched a cost transformation program expected to save $80M annually in 2027. Full-year 2026 guidance was narrowed, with revenue now expected between $2.52B-$2.54B.

A live results discussion is set for Nov. 3, after QuidelOrtho reports earnings.

QuidelOrtho (QDEL) will report Q3 2026 earnings on Nov. 3, followed by a conference call and webcast at 5:00 p.m. ET. The company is a global diagnostics provider, offering solutions for clinical chemistry, immunoassay, and molecular testing. Interested parties can access the live webcast on the company's Investor Relations page.

QuidelOrtho Corp (QDEL): Entry into a Material Definitive Agreement

QuidelOrtho Corp (QDEL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 23, 2026, QuidelOrtho Corporation (the “Company”) entered into Amendment No. 1 (the “Amendment”) to its existing credit agreement, dated as of August 21, 2025 (as amended by the Amendment, the “Credit Agreement”),

QDEL sentiment & insider activity

Recent QDEL coverage spans earnings, corporate actions and financial news.

What's driving QDEL

  • The earnings miss and lowered guidance likely pressure the stock.

    prnewswire.com · Nov 3, 2026

  • The earnings release may trigger short‑term volatility as investors digest the numbers and guidance.

    stocktitan.net · Oct 20, 2026

  • Amendment eases leverage covenants and sets lower interest rates, potentially improving liquidity and reducing financing costs.

    SEC EDGAR 8-K · Sep 23, 2026

  • Guidance reset plus negative cash flow and higher leverage risk likely shifts the market’s valuation toward balance-sheet and China execution risk, despite margin expansion.

    fool.com · Aug 14, 2026

  • The guidance cut is the dominant driver, implying weaker forward demand and/or margin pressure that can extend downside beyond the earnings beat.

    yahoo.com · Aug 10, 2026

AlphAI scores every news story that mentions QDEL with an AI model for sentiment and relevance, and aggregates insider trades from QuidelOrtho Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $QDEL

Score
$QDELHighAI 8/10Earnings

QuidelOrtho Reports Third Quarter 2026 Financial Results

QuidelOrtho (QDEL) reported Q3 2026 revenue of $619M, down 12% YoY. Excluding respiratory, China, and U.S. Donor Screening, revenue grew 2-3%. Labs revenue declined 6% due to China pricing changes, but grew 3-4% outside China. Point of Care revenue dropped 27% due to a softer respiratory season. The company launched a cost transformation program expected to save $80M annually in 2027. Full-year 2026 guidance was narrowed, with revenue now expected between $2.52B-$2.54B.

$QDELMedDebt financing· $1.15B

QuidelOrtho Corp (QDEL): Entry into a Material Definitive Agreement

QuidelOrtho Corp (QDEL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 23, 2026, QuidelOrtho Corporation (the “Company”) entered into Amendment No. 1 (the “Amendment”) to its existing credit agreement, dated as of August 21, 2025 (as amended by the Amendment, the “Credit Agreement”),

$QDELHighAI 9/10

QuidelOrtho (QDEL) Q2 2026 Earnings Call Transcript

QuidelOrtho (QDEL) reported Q2 2026 revenue of $630.9 million, up 1.9% constant-currency, with Labs $382.9 million, Immunohematology $134.2 million, and Point of Care $108.2 million. Adjusted EBITDA was $129.3 million (21% growth). China revenue fell 23.3% constant-currency. Full-year 2026 guidance was lowered to $2.52-$2.60 billion revenue and $540-$560 million adjusted EBITDA, with adjusted EPS $0.65-$0.90.

$QDELHighAI 9/10

Why QuidelOrtho (QDEL) Stock Is Nosediving

QuidelOrtho (QDEL) shares fell 21.3% after the company cut its full-year revenue and adjusted EPS outlook despite a Q2 beat. Q2 revenue was $630.9M and adjusted EPS $0.13. Full-year guidance was lowered to $2.52B-$2.6B revenue and adjusted EPS of $0.65-$0.90, with the midpoint below analyst estimates.

$QDELHighGuidance· lower · $2.52B–$2.6B

QuidelOrtho Reports Second Quarter 2026 Financial Results

QuidelOrtho Corp (QDEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 QuidelOrtho Reports Second Quarter 2026 Financial Results ― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth― ― Excluding China, total revenue grew 6% both as reported and in constant currency ― ― Company upda

QuidelOrtho (QDEL) To Report Earnings Tomorrow: Here Is What To Expect

QuidelOrtho (QDEL) will report earnings Thursday after the bell. The company missed last quarter’s revenue expectations, with revenue of $619.8M, down 10.5% YoY, and also missed EPS guidance and EPS estimates. For this quarter, analysts expect revenue flat YoY. QDEL is down 2.4% over the past month versus an average peer gain; average analyst price target is $21.33 vs $17.58.

Related tickers